Kisqali Approved by FDA to Treat Hormone-Receptor-Positive, Advanced-Stage Disease

Ribociclib (Kisqali) has been approved by the U.S. Food and Drug Administration to be used in combination with an aromatase inhibitor to treat advanced-stage or metastatic, hormone-receptor-positive, HER2-negative breast cancer that hasn’t been treated with hormonal therapy yet in postmenopausal women.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.